Understanding The Evolving Landscape Of Anti-Obesity Medication (AOMs)

Obesity continues to impact the health and well-being of over 40% of U.S. adults. As the need for effective treatment grows, so does the conversation surrounding anti-obesity medications (AOMs). In a recent interview, Shaila Yoshida, Assistant Director, Value & Access Strategy at Cencora, shares key findings from her latest research into payer coverage trends for these therapies.

She discusses the concerns payers face, the strategies they're using, and the shift from employer rider policies to standard commercial formularies. Shaila also highlights how real-world evidence and medical cost offsets can play a critical role in shaping future coverage decisions. Tune into this interview below to stay informed on this dynamic and rapidly evolving landscape.